Sep 11, 2018
A silo mentality is an issue for any organisation, but it is particularly problematic for the pharmaceutical industry. Drug development is a multidisciplinary endeavour that relies on the cumulative efforts of highly skilled teams in order to be successful. Yet these teams cannot work in isolation.
Few development challenges reside within their own ‘bubble’; without careful planning and good communication, the solutions adopted to overcome one obstacle can have a significant knock-on effect elsewhere in the development pipeline. As a result, fragmented thinking can lead to poor decision-making, costly hold-ups, and even contribute to the failure of entire programmes.
In this episode, we consider the symptoms and consequences of a silo culture in drug development, and look at how interdisciplinary integration should be at the heart of every pharma business model.
Original article by Dr Paul Overton
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: